Palmitoyl Tetrapeptide-7 vs ANP (Atrial Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Side-by-Side Comparison
| Aspect | Palmitoyl Tetrapeptide-7 | ANP (Atrial Natriuretic Peptide) |
|---|---|---|
| Mechanism | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. |
| Typical Dosage | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. |
| Administration | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. |
| Side Effects | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. |
| Best For |